饶丹宁甲叉基取代左氧氟沙星衍生物的合成与抗肿瘤活性

doi:10.19894/j.issn.1000-0518.200199

摘要/Abstract

摘要： 为寻找提高氟喹诺酮肿瘤活的有效结构修饰策略,左氧氟沙星(3)的衍生物(S)-(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-[1,4] 噁嗪并[2,3,4-ij]-喹啉-7(4H)-酮-6-甲醛(5)与饶丹宁类(2a-2l)通过Claisen-Schmid缩合反应构建了饶丹宁甲叉基取代左氧氟沙星衍生物(6a-6l)目标化合物,其结构经元素分析和光谱数据确证。体外初步抗细胞增殖活性筛选结果表明,12个新目标化合物对人非小细胞肺癌细胞(A549)、人肝癌细胞(Hep-3B)、人胰腺癌细胞(Capan-1)和人白血病细胞(HL60)的活性高于母体左氧氟沙星,且对正常细胞Vero表现出较低细胞毒作用。构效关系表明,卤代苯基或饶丹宁或环丙基饶丹宁化合物的活性强于其它取代,尤其环丙基化合物对A549的活性与对照阿霉素相当。因此,饶丹宁甲叉基替代C-3羧基有利于提高氟喹诺酮的抗肿瘤活性,发展了氟喹诺酮结构修饰的新途径。

关键词: 氟喹诺酮, 饶丹宁, 不饱和酮, 生物电子等排体, 抗肿瘤活性

Abstract: To explore an efficient structural modification strategy to enhance the antitumor activity of fluoroquinolones, a methane-rhodanine fragment was used as the bioisosteric replacement of the C-3 carboxylic acid group and consequently twelve new C-3 α,β-unsaturated thiazolone derivatives (6a-6l) were designed and synthesized by Claisen-Schmid condensation reaction with oxazinoquinolin-7-one-6-carbaldehyde (5) derived from levofloxacin (1) and N-substituted rhodanines (2a-2l), respectively. The in vitro antitumor activity of the synthesized compounds is more potent than that of levofloxacin along with lower cytotoxicity against Vero cells. Meanwhile, the structure-activity relationship (SAR) reveals that halophenyl, N-unsubstituted or cyclopropyl rhodaninec ompounds display a better activity than those of the control compounds, especially the IC₅₀ values of cyclopropyl rhodanine compound (6j) against A549 cell growth is comparable to doxorubicin. Thus, an unsaturated ketone annulated rhodanine scaffold as a bioisostere of the C-3 carboxylic acid group is found to be an alternative proposal for improving the antitumor activity of fluoroquinolones. Furthermore, whether an α,β-unsaturated ketone fragment is a promising bioisostere of the C-3 carboxylic acid group is worth further developing.

Key words: Fluoroquinolone, Rhodanine, Unsaturated ketone, Bioisostere, Antitumor activity

中图分类号:

O626.2

张会丽, 崔红艳, 黄文龙, 胡国强. 饶丹宁甲叉基取代左氧氟沙星衍生物的合成与抗肿瘤活性[J]. 应用化学, 2021, 38(2): 188-194.

ZHANG Hui-Li, CUI Hong-Yan, HUANG Wen-Long, HU Guo-Qiang. Synthesis and Antitumor Activity of Rhodanine Methylene-Substituted Levofloxacin Derivatives[J]. Chinese Journal of Applied Chemistry, 2021, 38(2): 188-194.

参考文献

[1] ABDOLMALEKI A, GHASEMI J B. Dual-acting of hybrid compounds-a new dawn in the discovery of multi-target drugs:lead generation approaches[J]. Curr Top Med Chem,2017, 17(9):1096-1114.
[2] BATTINI L, BOLLINI M. challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors[J]. Med Res Rev, 2019, 39(4):1235-1273.
[3] CHO S, KIM S H, SHIN D. Recent applications of hydantoin and thiohydantoin in medicinal chemistry[J]. Eur J Med Chem, 2019, 164:517-545.
[4] KAMINSKYY D, KRYSHCHYSHYN A, LESYK R. Recent developments with rhodanine as a scaffold for drug discovery[J]. Expert Opin Drug Discov, 2017, 12(12):1233-1252.
[5] ZHUANG C,ZHANG W,SHENG C, et al. Chalcone:a privileged structure in medicinal chemistry[J]. Chem Rev, 2017, 117(12):7762-7810.
[6] MIGNANI S, EL BRAHMI N, EL KAZZOULI S, et al. A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action[J]. Eur J Med Chem, 2016, 122:656-673.
[7] CORTÉS-BENÍTEZ F, CABEZA M, RAMÍREZ-APAN M T, et al. Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line[J]. Eur J Med Chem, 2016, 121:737-736.
[8] SONG M. Progress in discovery of KIF5B-RET kinase inhibitors for the treatment of non-small-cell lung cancer[J]. J Med Chem, 2015, 59(9):3672-3681.
[9] JACKSON P A, WIDEN J C, HARKI D A, et al. Covalent modifiers:a chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via hetero-michael addition reactions[J]. J Med Chem, 2017, 60(3):839-885.
[10] KAMINSKYY D, KRYSHCHYSHYN A, LESYK R. 5-Ene-4-thiazolidinones-an efficient tool in medicinal chemistry[J]. Eur J Med Chem, 2017, 140:542-549.
[11] SKOK Ž, ZIDAR N, KIKELJ D, et al. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets[J]. J Med Chem, 2020, 63(3):884-904.
[12] SUAIFAN G A R Y, MOHAMMED A A M. Fluoroquinolones structural and medicinal developments (2013-2018):where are we now?[J]. Bioorg Med Chem, 2019, 27(14):3005-3060.
[13] YOU Q D, LI Z Y, HUANG C H, et al. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification[J]. J Med Chem, 2009, 52(18):5649-5661.
[14] HU W, HUANG X S, WU J F, et al. Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches[J]. J Med Chem, 2018, 61(20):8947-8980.
[15] 李元元, 张呈霞, 黄文龙, 等. 左氧氟沙星的噻唑并均三唑衍生物的合成及抗肿瘤活性[J]. 应用化学, 2019, 36(6):671-676.
LI Y Y, ZHANG C X, HUANG W L, et al. Synthesis and antitumor activities of C-3 thiazolotriazole unsaturated Ketone derivatives of levofloxacoin[J]. Chinese J Appl Chem,2019, 36(6):671-676.
[16] 张会丽, 李珂, 黄文龙, 等. N-(5-芳苄叉基饶丹宁)左氧氟沙星酰胺的合成及抗肿瘤活性[J]. 应用化学, 2019, 36(8):897-903.
ZHANG H L, LI K, HUANG W L, et al. Synthesis and antitumor activity of N-arylidene-rhodanine levofloxacin amides[J]. Chinese J Appl Chem, 2019, 36(8):897-903.
[17] HU G Q, WANG G Q, DUAN N N, et al. Design, synthesis and antitumor activity of fluoroquinolone C3 heterocyclic bis-oxadiazole methylsulfide derivatives derived from levofloxacin[J]. Chem Res Chinese Univ, 2012, 28(6):980-984.
[18] BROWN F C, BRADSHER C K, MORGAN E C, et al. Some 3-substituted rhodanines[J]. J Am Chem Soc, 1956, 78:384-388.
[19] 陈立华, 谢蓝, 谢晶曦. 五味子醇甲类似物的全合成[J]. 药学学报, 1991, 26(1):20-24.
CHEN L H,XIE L,XIE J Z. Total synthesis of an analogue of schizandrin[J]. Acta Pharm Sin, 1991, 26(1):20-24.
[20] MA B, BANERJEE B, LITVINOV D N, et al. Total synthesis of the antimitotic bicyclic peptide celogentin C[J]. J Am Chem Soc, 2010, 132(3):1159-1171.